Appili Therapeutics Inc.

TSX:APLI Stock Report

Market Cap: CA$4.2m

Appili Therapeutics Management

Management criteria checks 2/4

Appili Therapeutics' CEO is Don Cilla, appointed in Nov 2022, has a tenure of 2.08 years. total yearly compensation is CA$622.60K, comprised of 80.4% salary and 19.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth CA$2.63K. The average tenure of the management team and the board of directors is 2.1 years and 5.6 years respectively.

Key information

Don Cilla

Chief executive officer

CA$622.6k

Total compensation

CEO salary percentage80.4%
CEO tenure2.1yrs
CEO ownership0.06%
Management average tenure2.1yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Mar 24
Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

Dec 09
Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

CEO Compensation Analysis

How has Don Cilla's remuneration changed compared to Appili Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$4m

Jun 30 2024n/an/a

-CA$4m

Mar 31 2024CA$623kCA$501k

-CA$4m

Dec 31 2023n/an/a

-CA$5m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$8m

Mar 31 2023CA$608kCA$433k

-CA$9m

Dec 31 2022n/an/a

-CA$10m

Sep 30 2022n/an/a

-CA$11m

Jun 30 2022n/an/a

-CA$20m

Mar 31 2022CA$747kCA$477k

-CA$25m

Dec 31 2021n/an/a

-CA$27m

Sep 30 2021n/an/a

-CA$28m

Jun 30 2021n/an/a

-CA$19m

Mar 31 2021CA$627kCA$170k

-CA$14m

Compensation vs Market: Don's total compensation ($USD432.81K) is above average for companies of similar size in the Canadian market ($USD164.06K).

Compensation vs Earnings: Don's compensation has increased whilst the company is unprofitable.

CEO

Don Cilla

2.1yrs

Tenure

CA$622,595

Compensation

Dr. Donald D. Cilla, also known as Don, Jr., PharmD, MBA, serves as Chief Executive Officer, President and Director at Appili Therapeutics Inc. since November 13, 2022 and served as its Chief Development O...

Leadership Team

NamePositionTenureCompensationOwnership
Donald Cilla
CEO, President & Director2.1yrsCA$622.60k0.062%
CA$ 2.6k
Kenneth Howling
Chief Financial Officer3.1yrsCA$499.44kno data
Gary Nabors
Chief Development Officer1.7yrsCA$548.01kno data
Carl Gelhaus
Director of Non-Clinical Researchno dataCA$301.26kno data
Arthur Baran
Director of New Product Developmentno dataCA$313.76kno data

2.1yrs

Average Tenure

Experienced Management: APLI's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Donald Cilla
CEO, President & Director2.1yrsCA$622.60k0.062%
CA$ 2.6k
Lidija Marusic
Board Observer5.6yrsno datano data
Prakash Gowd
Independent Director1.1yrsCA$30.23kno data
Lynn Silver
Member of Advisory Boardno datano datano data
Dean Shinabarger
Member of Advisory Boardno datano datano data
Brian Bloom
Independent Director9.6yrsCA$63.10kno data
Juergen Froehlich
Independent Director4.9yrsCA$84.10kno data
Armand Balboni
Chairman of the Board5.8yrsCA$39.00kno data
Theresa Matkovits
Lead Independent Director6.2yrsCA$131.60kno data
Sridhar Narayan
Member of Scientific Advisory Boardno datano datano data

5.6yrs

Average Tenure

58yo

Average Age

Experienced Board: APLI's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Appili Therapeutics Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chelsea StellickiA Capital Markets
Douglas LoeLeede Jones Gable Inc
Andre UddinResearch Capital Corporation